Antipsychotic-induced venous thromboembolism: A review of the evidence

CNS Drugs

Volumn 16, Issue 11, 2002, Pages 765-776

  Hägg, Staffan ^a   Spigset, Olav ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ANTIESTROGEN; ANXIOLYTIC AGENT; BENZATROPINE; CHLORPROMAZINE; CLONAZEPAM; CLOZAPINE; FLUPENTIXOL; FLUPHENAZINE; GESTAGEN; HALOPERIDOL; HEPARIN; IMIPRAMINE; LEPTIN; LEVOMEPROMAZINE; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; ORAL CONTRACEPTIVE AGENT; PAROXETINE; PERPHENAZINE; PHOSPHOLIPID ANTIBODY; RESERPINE; THIORIDAZINE; TRIFLUOPERAZINE; ZOTEPINE;

ADOLESCENT; ADULT; AGED; BLOOD CLOTTING DISORDER; BODY WEIGHT DISORDER; DISEASE PREDISPOSITION; DROWSINESS; DRUG POTENCY; FEMALE; HEART INFARCTION; HUMAN; LUNG EMBOLISM; MALE; OBESITY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEDATION; SMOKING; THORAX PAIN; THROMBOEMBOLISM; VEIN THROMBOSIS;

ANTIPSYCHOTIC AGENTS; BLOOD COAGULATION; BODY WEIGHT; HUMAN; PSYCHOTIC DISORDERS; RESTRAINT, PHYSICAL; RISK FACTORS; SMOKING; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 0036035023     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200216110-00005     Document Type: Review

References (77)

1. Goldhaber SZ. Clinical overview of venous thrornboembolism. Vasc Med 1998; 3: 35-40
2. Kahn SR, Solymoss S, Lamping DL, et al. Long-term outcomes after deep vein thrombosis: Postphlebitic syndrome and quality of life. J Gen Intern Med 2000; 15: 425-9
3. Rosendaal FR. Risk factors for venous thrombotic disease. Thromb Haemost 1999; 82: 610-9
4. Motykie GD, Zebala LP, Caprini JA, et al. A guide to venous thromboembolism risk factor assessment. J Thromb Thrombolysis 2000; 9: 253-62
5. Brehmer G, Ruckdeschel KT. Zur technik der winterschlafbehandlung. Dtsch Med Wochenschr 1953; 78: 1724-5
6. Labhardt E. Technik, nebenerscheinungen und komplikationen der Largactil therapie. Schweiz Arch Neurol Psychiatr 1954; 73: 338-44
7. Lunel G, Noble Y, Arne L. The thrombogenic role of neuroleptic agents (apropos of 2 cases) [in French]. Bord Med 1972; 5: 121-6
8. Ruh-Bernhardt D, Finance F, Rohmer F, et al. Influence of psychotropic therapy on thrombogenesis and platelet functions: A propos of 4 cases of thromboembolic accidents occurring in patients treated by neuroleptics and antidepressants [in French]. Encephale 1976; 2: 239-55
9. Singer L, Finance F, Ruh D. Pulmonary embolisms occurring in 1 month in 3 aged women with manic-depressive psychoses. Discussion: Etiopathogenic role or psychiatric treatment [in French]. Ann Med Psychol (Paris) 1975; 1: 256-63
10. Varia I, Krishnan RR, Davidson J. Deep-vein thrombosis with antipsychotic drugs. Psychosomatics 1983; 24: 1097-8
11. Maurice H. Des complications phlepitiques au cours des traitements par les neuroleptiques. Encephale 1956; 51: 797-801
12. Grahmann H, Suchenwirth R. Thrombose hazard in chlorpromazine and reserpine therapy of endogenous psychosis [in German]. Nervenarzt 1959; 30: 224-5
13. Häfner H, Brehm I. Thromboembolic complications in neuroleptic treatment. Compr Psychiatry 1965; 6: 25-34
14. Meier-Ewert K, Baumgart HH, Friedenberg P. Thromboembolism complications in neuro- and thymoleptic therapy [in German]. Dtsch Med Wochenschr 1967; 92: 2174-8
15. Scholtz V. Concerning the thromboembolic complications from neuroleptic drugs [in German]. Nervenarzt 1967; 38: 174-7
16. Lal S, Bleiman M, Brown BN. Pulmonary embolism in psychiatric patients. J Am Geriatr Soc 1966; 14: 1138-43
17. Mahmodian MH. Ursachen der lungenembolie bei psychisch und neurologisch Kranken. Arch Psychiatr Nervenkr 1963; 204: 229-44
18. Kendel K, Fodor S. Pulmonary embolism and symptomatic psychosis. Ger Med Mon 1969; 14: 184-7
19. Ziegler HK. Lungenembolie aus der sicht des pathologen. Med Klin 1977; 72: 1063-70
20. Walker AM, Lanza LL, Arellano F, et al. Mortality in current and former users of clozapine. Epidemiology 1997; 8: 671-7
21. Hägg S, Spigset O, Söderström TG. Association of venous thromboembolism and clozapine. Lancet 2000; 355: 1155-6
22. Zornberg GL, Jick H. Antipsychotic drug use and risk of firsttime idiopathic venous thromboembolism: A case-control study. Lancet 2000; 356: 1219-23
23. Modai I, Hirschmann S, Rava A, et al. Sudden death in patients receiving clozapine treatment: A preliminary investigation. J Clin Psychopharmacol 2000; 20: 327-37
24. Thomassen R, Vandenbroucke JP, Rosendaal FR. Antipsychotic medication and venous thrombosis. Br J Psychiatry 2001; 179: 63-6
25. Lilleng P, Morild I, Hope M. Clozapine and myocarditis [in Norwegian]. Tidsskr Nor Laegeforen 1995; 115: 3026-7
26. Vogel U, Jurgeleit MP, Bultmann B. The economy class syndrome. Deep vein thrombosis and pulmonary embolism after air travel: Neuroleptic therapy a risk factor? [in German]. Munch Med Wochenschr 1998; 140: 421-3
27. Lacika S, Cooper JP. Pulmonary embolus possibly associated with clozapine treatment [letter]. Can J Psychiatry 1999; 44: 396-7
28. Suttmann I, Dittert S, Landgraf R, et al. Clozapine and sudden death [letter]. Lancet 2000; 355: 842-3
29. Maynes D. Bilateral pulmonary embolism in a patient on clozapine therapy [letter]. Can J Psychiatry 2000; 45: 296-7
30. Coodin S, Ballegeer T. Clozapine therapy and pulmonary embolism [letter]. Can J Psychiatry 2000; 45: 395
31. Ihde-Scholl T, Rolli ML, Jefferson JW. Clozapine and pulmonary embolus [letter]. Am J Psychiatry 2001; 158: 499-500
32. Osby U, Correia N, Brandt L, et al. Time trends in schizophrenia mortality in Stockholm County, Sweden: Cohort study. BMJ 2000; 321: 483-4
33. Brown S. Excess mortality of schizophrenia: A meta-analysis. Br J Psychiatry 1997; 171: 502-8
34. Dukes MNG, Aronson JK, editors. Meyler's Side Effects of Drugs. 14th Rev. Ed. Amsterdam: Elsevier, 2000
35. Vandenbroucke JP, Bertina RM, Holmes ZR, et al. Factor V Leiden and fatal pulmonary embolism. Thromb Haemost 1998; 79: 511-6
36. Thorogood M, Cowen P, Mann J, et al. Fatal myocardial infarction and use of psychotropic drugs in young women. Lancet 1992; 340: 1067-8
37. Knudson JF, Kortepeter C, Dubitsky GM, et al. Antipsychotic drugs and venous thromboembolism [letter]. Lancet 2000; 356: 252-3
38. Wolstein J, Grohmann R, Ruther E, et al. Association of venous thromboembolism and clozapine [letter]. Lancet 2000; 356: 252
39. Clardy J, Gale RH. Mortality risk and clozapine [letter]. Am J Psychiatry 1995; 152: 651
40. Pantel J, Schroder J, Eysenbach K, et al. Two cases of deep vein thrombosis associated with a combined paroxetine and zotepine therapy. Pharmacopsychiatry 1997; 30: 109-11
41. McCall WV, Mann SC, Shelp FE, et al. Fatal pulmonary embolism in the catatonic syndrome: Two case reports and a literature review [letter]. J Clin Psychiatry 1995; 56: 21-5
42. Sukov RJ. Thrombophlebitis as a complication of severe catatonia [letter]. JAMA 1972; 24: 587-8
43. Hindersin P, Siegmund R. Körting HJ. Thrombophilic diatheses as hemostasis disorders in acute psychoses [in German]. Psychiatr Neurol Med Psychol (Leipz) 1984; 36: 702-9
44. Lazarus A. Physical restraints, thromboembolism, and death in 2 patients [letter]. J Clin Psychiatry 2001; 62: 207-8
45. Hem E, Steen O, Opjordsmoen S. Thrombosis associated with physical restraints. Acta Psychiatr Scand 2001; 103: 73-5
46. Wagstaff AJ, Bryson HM. Clozapine: A review of its pharmacological properties and therapeutic use in patients with schizophrenia who are unresponsive to or intolerant of classical antipsychotic agents. CNS Drugs 1995; 4: 370-400
47. Owens DG. Adverse effects of antipsychotic agents: Do newer agents offer advantages? Drugs 1996; 51: 895-930
48. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: A comprehensive research synthesis. Am J Psychiatry 1999; 156: 1686-96
49. Eckel RH. Obesity and heart disease: A statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation 1997; 96: 3248-50
50. Rexrode KM, Manson JE, Hennekens CH. Obesity and cardiovascular disease. Curr Opin Cardiol 1996; 11: 490-5
51. Timar O, Sestier F, Levy E. Metabolic syndrome X: A review. Can J Cardiol 2000; 16: 779-89
52. de Courten M, Zimmet P, Hodge A, et al. Hyperleptinaemia: The missing link in the, metabolic syndrome? Diabet Med 1997; 14: 200-8
53. Söderberg S, Olsson T, Eliasson M, et al. Plasma leptin levels are associated with abnormal fibrinolysis in men and postmenopausal women. J Intern Med 1999; 245: 533-43
54. Greaves M. Antiphospholipid antibodies and thrombosis. Lancet 1999; 353: 1348-53
55. Schwartz M, Rochas M, Toubi E, et al. High association of anticardiolipin antibodies with psychosis. J Clin Psychiatry 1998; 59: 20-3
56. Canoso RT, de Oliveira RM. Chlorpromazine-induced anticardiolipin antibodies and lupus anticoagulant: Absence of thrombosis. Am J Hematol 1988; 27: 272-5
57. Canoso RT, de Oliveira RM, Nixon RA. Neuroleptic-associated autoantibodies: A prevalence study. Biol Psychiatry 1990; 27: 863-70
58. Metzer WS, Canoso RT, Newton JEO. Anticardiolipin antibodies in a sample of chronic schizophrenics receiving neuroleptic therapy. South Med J 1994; 87: 190-2
59. Steen VD, Ramsey-Goldman R. Phenothiazine-induced systemic lupus erythematosus with superior vena cava syndrome: Case report and review of the literature. Arthritis Rheum 1988; 31: 923-6
60. el-Mallakh RS, Donaldson JO, Kranzler HR, et al. Phenothiazineassociated lupus anticoagulant and thrombotic disease. Psychosomatics 1988; 29: 109-13
61. Ayuso JL, Ruiz JS. Neuroleptic-induced antinuclear antibodies [letter]. Eur Psychiatry 1996; 11: 378-9
62. Davis S, Kern HB, Asokan R. Antiphospholipid antibodies associated with clozapine treatment [letter]. Am J Hematol 1994; 46: 166-7
63. Chengappa KN, Carpenter AB, Keshavan MS, et al. Elevated IGG and IGM anticardiolipin antibodies in a subgroup of medicated and unmedicated schizophrenic patients. Biol Psychiatry 1991; 30: 731-5
64. Firer M, Sirota P, Schild K, et al. Anticardiolipin antibodies are elevated in drug-free, multiply affected families with schizophrenia. J Clin Immunol 1994; 14: 73-8
65. Roche-Bayard P, Rossi R, Mann JM, et al. Left pulmonary artery thrombosis in chlorpromazine-induced lupus [letter]. Chest 1990; 98: 1545
66. Boullin DJ, Woods HF, Grimes RPJ, et al. Increased platelet aggregation responses to 5-hydroxytryptamine in patients taking chlorpromazine. Br J Clin Pharmacol 1975; 2: 29-35
67. Boullin DJ, Grahame-Smith DG, Grimes RPJ, et al. Inhibition of 5-hydroxytryptamine-induced human blood platelet aggregation by chlorpromazine and its metabolites. Br J Pharmacol 1975; 53: 121-5
68. Boullin DJ, Knox JM, Peters JR, et al. Platelets aggregation and chlorpromazine therapy [letter]. Br J Clin Pharmacol 1978; 6: 538-40
69. Orr MW, Boullin DJ. The relationship between changes in 5HT induced platelet aggregation and clinical state in patients treated with fluphenazine. Br J Clin Pharmacol 1976; 3: 925-8
70. Orr MW, Knox JM, Allen R, et al. The effects of neuroleptic drugs on 5-hydroxytryptamine induced platelet aggregation in schizophrenic patients. Br J Clin Pharmacol 1981; 11: 255-9
71. Hughes JR, Hatsukami DK, Mitchell JE, et al. Prevalence of smoking among psychiatric outpatients. Am J Psychiatry 1986; 143: 993-7
72. Beratis S, Katrivanou A, Gourzis P. Factors affecting smoking in schizophrenia. Compr Psychiatry 2001; 42: 393-402
73. Goldhaber SZ, Grodstein F, Stampfer MJ, et al. A prospective study of risk factors for pulmonary embolism in women. JAMA 1997; 277: 642-5
74. Danilenko-Dixon DR, Heit JA, et al. Risk factors for deep vein thrombosis and pulmonary embolism during pregnancy or post partum: A population-based, case-control study. Am J Obstet Gynecol 2001; 184: 104-10
75. Anello C, O'Neill R. Does research synthesis have a place in drug regulatory policy? Synopsis of issues: Assessment of safety and postmarketing surveillance. Clin Res Regul Aff 1996; 13: 13-21
76. Venning G. Identification of adverse reactions to new drugs. IV: Verification of suspected adverse reactions. BMJ 1983; 286: 544-7
77. Vandenbroucke JP, Rosing J, Bloemenkamp KW, et al. Oral contraceptives and the risk of venous thrombosis. N Engl J Med 2001; 344: 1527-35